News | Biopsy Systems | March 16, 2017

Exact Imaging Announces Health Canada Approval and License for ExactVu Micro-Ultrasound System

First Canadian customer will use prostate biopsy system in study to better understand apoptosis and how cancerous cells respond to therapy

Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota

March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#98667) to sell its ExactVu high resolution micro-ultrasound biopsy system in Canada. The first device was sold to Gregory Czarnota, M.D., and Sunnybrook Health Sciences Centre and Sunnybrook Research Institute in Toronto.

"The unmatched resolution of the ExactVu micro-ultrasound system will provide important capabilities to our urologists in helping them actually visualize and distinguish suspicious tissue — and therefore allows us to actually target our prostate biopsies," said Czarnota, director of the Odette Cancer Research Program, Sunnybrook Research Institute and Radiation Oncologist at Sunnybrook Health Sciences Centre. "Furthermore, the ExactVu's high resolution imaging also generates rich RF (or radiofrequency) data which our research teams can evaluate and correlate with pathology to apply against our models to better understand apoptosis and how cancerous cells respond to therapy. We see very exciting potential in the ExactVu system and look forward to our collaboration with the team at Exact Imaging."

Czarnota discovered that high-frequency ultrasound could be used to detect apoptosis or cell death. This finding has since been applied to important questions in oncology and organ transplantation. Czarnota's research group is investigating a number of spectroscopic parameters for characterizing tumors and tumor responses to chemotherapy and radiation therapy at high frequencies and intends to use the ExactVu for such purposes. Specific applications include developing methods to generate color-coded ultrasound parametric maps to aid in assessing tumor responses to therapy. Since these spectroscopic signals are potentially linked to nuclear structure and chromatin structure that differs between normal and neoplastic tissue, there is potential to develop our spectroscopic methods not only into a method to track tumor responses but a potentially important diagnostic tool.

For more information: www.exactimaging.com

Related Content

Konica Minolta Supports Educational Workshops at Physical Medicine and Rehabilitation Meeting
News | Ultrasound Imaging | October 16, 2017
Konica Minolta Healthcare Americas Inc. supported ultrasound education for physiatrists in physical medicine and...
Illinois Hospital Grows Pediatric Imaging Capabilities with Toshiba Aplio i800 Ultrasound
News | Ultrasound Imaging | October 16, 2017
To expand ultrasound capabilities in its radiology department and offer safe, less invasive imaging to its pediatric...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
Toshiba Medical to Highlight Aplio i-Series Ultrasound at RSNA 2017
News | Ultrasound Imaging | October 11, 2017
October 11, 2017 — Toshiba Medical’s Aplio i-series is a highly advanced...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
Carestream Showcases Imaging and Healthcare IT Systems at RSNA 2017
News | Information Technology | October 10, 2017
October 10, 2017 — Carestream will be highlighting several of its imaging systems and healthcare...
Stanford Trial Demonstrates Accuracy of Accuro Image-Guided Epidural System
News | Ultrasound Imaging | October 09, 2017
October 9, 2017 — A clinical trial conducted at Stanford University Medical Center...
Toshiba Medical's Portable Ultrasound Used in Second Pediatric Mission in Tanzania
News | Ultrasound Imaging | October 05, 2017
October 5, 2017 — To provide lifesaving surgical care for sick children in one of the most underserved countries, 13
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Immune Response Prognostic for Prostate Cancer Survival, Recurrence and Radiotherapy Response
News | Prostate Cancer | October 03, 2017
A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to...
Overlay Init